Trevi Therapeutics Inc [NASDAQ: TRVI] loss -0.53% or -0.02 points to close at $3.76 with a heavy trading volume of 258526 shares.
The daily chart for TRVI points out that the company has recorded 41.35% gains over the past six months.
If we look at the average trading volume of 1.76M shares, TRVI reached to a volume of 258526 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Trevi Therapeutics Inc [TRVI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TRVI shares is $9.65 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TRVI stock is a recommendation set at 1.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Trevi Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 12, 2024. While these analysts kept the previous recommendation, Leerink Partners raised their target price from $6 to $7. The new note on the price target was released on September 09, 2024, representing the official price target for Trevi Therapeutics Inc stock. Previously, the target price had yet another raise to $9, while Raymond James analysts kept a Outperform rating on TRVI stock.
The Average True Range (ATR) for Trevi Therapeutics Inc is set at 0.31 The Price to Book ratio for the last quarter was 4.81, with the Price to Cash per share for the same quarter was set at 0.73.
Trading performance analysis for TRVI stock
Trevi Therapeutics Inc [TRVI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.57. With this latest performance, TRVI shares dropped by -11.32% in over the last four-week period, additionally plugging by 41.35% over the last 6 months – not to mention a rise of 178.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TRVI stock in for the last two-week period is set at 48.02, with the RSI for the last a single of trading hit 41.84, and the three-weeks RSI is set at 50.96 for Trevi Therapeutics Inc [TRVI]. The present Moving Average for the last 50 days of trading for this stock 3.43, while it was recorded at 3.86 for the last single week of trading, and 3.04 for the last 200 days.
Trevi Therapeutics Inc [TRVI]: A deeper dive into fundamental analysis
Trevi Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.38 and a Current Ratio set at 7.38.
An analysis of Institutional ownership at Trevi Therapeutics Inc [TRVI]
There are presently around $70.47%, or 71.21%% of TRVI stock, in the hands of institutional investors. The top three institutional holders of TRVI stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 11.37 million shares, which is approximately 11.4255%. FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding 7.38 million shares of the stock with an approximate value of $$22.0 million in TRVI stocks shares; and FRAZIER LIFE SCIENCES MANAGEMENT, L.P., currently with $$14.98 million in TRVI stock with ownership which is approximately 5.0513%.
